Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

• Published in: Arthritis & rheumatology (Hoboken, N.J.) Vol. 70; no. 8; pp. 1256 - 1264
• Main Authors: Doria, A., Stohl, W., Schwarting, A., Okada, M., Scheinberg, M., Vollenhoven, R., Hammer, A. E., Groark, J., Bass, D., Fox, N. L., Roth, D., Gordon, D.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.08.2018; John Wiley and Sons Inc
• Subjects: Adult; Antibodies, Antinuclear - blood; Antibodies, Antinuclear - immunology; Antibodies, Monoclonal, Humanized - administration & dosage; Autoimmune diseases; BLyS protein; Chronic conditions; Complement C3 - deficiency; Corticosteroids; Deoxyribonucleic acid; DNA; DNA - immunology; Double-Blind Method; Estrogens; Female; Humans; Immunosuppressive agents; Incidence; Injections, Subcutaneous; Intention to Treat Analysis; Lupus; Lupus Erythematosus, Systemic - blood; Lupus Erythematosus, Systemic - drug therapy; Lupus Erythematosus, Systemic - immunology; Lymphocytes B; Male; Monoclonal antibodies; Original; Patients; Safety; Severity of Illness Index; Stimulators; Systemic Lupus Erythematosus; Treatment Outcome

Objective To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti–double‐stranded DNA...